Eli Lilly (NYSE: LLY) Expands Zepbound and Foundayo Coverage Through CVS Caremark Formulary

Eli Lilly announced that CVS Caremark has added Zepbound and Foundayo to its formulary, significantly expanding insurance coverage for the company's obesity and weight-loss therapies. The move makes both drugs accessible to millions of CVS Caremark members across the United States, removing prior authorization barriers that may have limited patient access previously.

Zepbound (tirzepatide) and Foundayo (retatrutide) represent Lilly's next-generation GLP-1 receptor agonists competing in the rapidly growing obesity treatment market. The CVS Caremark formulary inclusion is a critical milestone for market penetration, as formulary placement directly affects prescriber adoption and patient affordability.

By the Numbers

• CVS Caremark serves millions of covered lives across the US health plan ecosystem
• Zepbound and Foundayo are now covered with fewer insurance barriers under CVS Caremark plans
• The formulary inclusion follows similar placements by other major pharmacy benefit managers

Why It Matters

Formulary coverage is a primary determinant of drug utilization in the US market. When a pharmacy benefit manager adds a therapy to its preferred drug list, it signals clinical validation and removes friction in the prescribing workflow. For Lilly, CVS Caremark's addition of both Zepbound and Foundayo simultaneously demonstrates confidence in the company's obesity pipeline and positions these drugs for broader uptake among the insurer's covered population.

The obesity treatment category has exploded following the commercial success of Novo Nordisk's Ozempic and Wegovy. Lilly's dual formulary win suggests the market is receptive to alternative GLP-1 products, particularly as supply constraints ease and physicians seek differentiated options. This coverage expansion removes one of the final gatekeepers between Lilly's sales force and eligible patients.

Wall Street View

Wolfe Research maintained a bullish stance on Lilly, citing confidence in the company's obesity pipeline as a significant long-term growth driver. Analysts have highlighted Foundayo's differentiation in the GLP-1 space, though broader market adoption remains dependent on clinical efficacy data, insurance coverage breadth, and manufacturing scale.

Investor Takeaway

The CVS Caremark formulary inclusion is a supply-side win that removes administrative hurdles to Zepbound and Foundayo prescribing. It does not confirm efficacy or commercial success, but it does meaningfully improve the probability of market adoption among eligible patients. For Lilly investors, formulary placements by major PBMs are necessary stepping stones in obesity drug commercialization—and this announcement checks that box.